A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors. The First Part of the Study is Completed and the Expansion Study is Ongoing (Reference Inclusion/Exclusion Criteria)
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Ciclopirox phosphoryloxymethyl ester (Primary)
- Indications Bladder cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors CicloMed
- 22 Nov 2019 Planned End Date changed from 31 Jul 2019 to 31 May 2020.
- 22 Nov 2019 Planned primary completion date changed from 31 Jul 2019 to 31 May 2020.
- 31 May 2019 Results assessing the phamacokinetics of ciclopirox prodrug for the treatment of bladder cancer, in animals and humans, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).